Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned

This article was originally published in The Pink Sheet Daily

Executive Summary

The global generics firm will rebrand Matrix, its Indian arm, as "Mylan," as it anticipates launching its prescription products in India under the Mylan label.
Advertisement

Related Content

Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout
After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout
Biologics Beckon: Biocon, Mylan Strike Deal; Combine To Take Teva, Sandoz Head-on

Topics

Advertisement
UsernamePublicRestriction

Register

PS072300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel